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Leprosy is in danger of being abandoned by the scientiﬁc community, just at a time when
real advances could be made in new molecular diagnostic assays. Although the number of
cases on treatment is still falling, there are still too many countries where large numbers of
new cases are being diagnosed.
1
It is likely that, as the lag period between exposure and
development of disease can be so long, new cases will continue to present. There is a very
real risk that as the focus on leprosy diminishes and as leprosy expertise is lost or diverted
to other public health problems, new cases will not be diagnosed and so will develop
irreversible nerve damage, as well as continuing the transmission chain.
There are a number of reasons why now is the time to focus on laboratory work on leprosy
and on leprosy diagnostics, but three seem of greatest importance in late 2011. Firstly there
has been extraordinary progress in new platform technologies that provide insight into disease
pathogenesis and that can identify the distinct biosignatures of infection, or of protection against
the development of disease. This is critical, as although Mycobacterium leprae itself can be
identiﬁed in multibacillary lepromatous leprosy patients, a simple read-out such as interferon-g
(IFN-g) produced in peripheral blood mononuclear cell cultures stimulated by M. leprae
antigens cannot distinguish between a healthy leprosy contact and a paucibacillary tuberculoid
leprosy patient. Techniques such as gene expression analysis using microarrays are identifying
gene pathways and genes that are up-regulated or down-regulated in tuberculosis,
2–5
and
there are anecdotal reports that many of these genes validate in different groups and cohorts.
The risk of obtaining too many false positives when analysing the expression of as many as
48,000 probes simultaneously is proving to be lower than expected, and the increased
or decreased gene expression identiﬁed using microarrays can usually be validated by PCR.
There are a number of ongoing multicentre studies and trials that are investigating the
biosignatures associated with TB disease, following the modulation of such proﬁles with
treatment, and monitoring TB contacts in longitudinal follow-up studies, to develop
biosignatures that predict control of latent TB infection, or progression to clinical tuberculosis.
Their ﬁndings will undoubtedly provide valuable insights into the immune response in leprosy.
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Moreover, once a few key genes of interest can be identiﬁed, assays based on existing
simple automated machines such as the GeneXpert assay for diagnosis of M. tuberculosis
infection
6
could be developed. Other multiplexing methodologies enable the analysis of
60–80 genes using reverse-transcriptase multiplex ligation-dependent probe ampliﬁcation.
7
Further new technologies for miniature ‘lab on a chip’ and lateral ﬂow assays
8
are
progressing so fast that such assays would be feasible at point of care, in a rural clinic without
access to a good laboratory.
Secondly, after many false starts, leprosy researchers are close to having leprosy antigens
with which to probe the immune response in an informative way. The early promise of
the M. leprae genome
9
was not fulﬁlled in terms of delivering M. leprae-speciﬁc antigens in
the initial research, and a number of studies have failed to identifyM. leprae-speciﬁc antigens
or to conﬁrm their speciﬁcity.
10–13
However, helped by improvements to the sensitivity
and speciﬁcity of these assays such as by combining peptides or adding cytokines,
14–15
some
promising candidates are being identiﬁed.
16–18
The tuberculosis ﬁeld was very lucky to
identify ESAT-6 and CFP-10 as (relatively) M. tuberculosis-speciﬁc antigens, which could
be exploited in interferon-gamma release assays,
19
but unfortunately there are T cell cross-
reactivities with the M. leprae ESAT-6 antigen which prevent the M. leprae homologue of
being useful as a diagnostic antigen.
20
So far it has been difﬁcult to identify M. leprae
antigens that are more sensitive and speciﬁc than phenolic glycolipid-I (PGL-I) for use in
serological assays for leprosy, although some antigens of interest are being identiﬁed;
17,21
this may be less surprising as the tuberculosis ﬁeld has also failed to develop speciﬁc antibody
tests for clinical tuberculosis.
22
In terms of cross-reactivity, it is still not quite clear whether
M. leprae is just a closer cousin to many environmental mycobacteria and thus many
M. leprae-antigens pick up cross-reactive T cell responses (there is no convincing evidence
that M. leprae can be found in the environment
23
), or whether high proportions of those
living in highly leprosy-endemic areas have been exposed to M. leprae. A number of
studies have picked up nasal carriage of M. leprae by PCR in healthy individuals living
in leprosy-endemic areas so exposure to M. leprae may be much more common than was
thought, although such carriage may be temporary
24–26
and it is not clear if it is associated
with detectable peripheral blood T cell recognition of M. leprae antigens.
The third reason for optimism is the huge progress being made in the tuberculosis vaccine
ﬁeld, from which leprosy research can beneﬁt. There are new TB vaccines in development
27
many of which might also protect against leprosy, just as BCG does. And the associated
search for correlates of protection should also provide the leprosy ﬁeld with useful new
knowledge, as discussed above.
There are further examples where the leprosy ﬁeld can learn from tuberculosis, despite
the fact that M. leprae has a down-sized genome compared to M. tuberculosis, and a
predilection for nerves.
1,9
However it is a member of the same family and so a lot can be
learnt from work on M. tuberculosis. The importance of TNF-a in tuberculosis was shown
by the progression to clinical tuberculosis when patients with latent tuberculosis infection
were given monoclonal antibody therapy to block TNF-a, and there has been a recent
description of a patient who developed leprosy when given the same therapy.
28
Latent
M. tuberculosis infection is now recognised to be a more active process than a lazy deep
sleep, with the associated expression of particular genes
29
and there may be lessons for
leprosy as more is learnt about the M. tuberculosis dosR-related, enduring hypoxia response
and resuscitation-related genes. We are also learning more about how M. tuberculosis
subverts the immune system, interfering with normal macrophage function, antigen
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presentation and T cell immunity.
30–33
Despite its slow growth rate, M. leprae is also a
pathogen that blocks the development of effective immune responses at least partly due to the
effects of phenolic glycolipid-I,
34,35
and that controls its intracellular environment. Otherwise,
how could it multiply to produce the numbers of M. leprae found in lepromatous leprosy
patients?
Leprosy has been privileged to have highly dedicated clinical and nursing staff who have
devoted their lives, sometimes at great cost, to helping leprosy patients. The leprosy ﬁeld also
has a small band of dedicated researchers, who have refused the seductive call of tuberculosis
as a research area. Although a lot of progress has beenmade in leprosy research, we still need to
identify what are the best antigens to use to dissect the immune response to M. leprae,
exploiting our knowledge of its genome sequence. Combining these speciﬁc antigens in a
simple test that will discriminate betweenM. leprae exposure andM. leprae disease (or likely
progression to disease) has been the target ofmuch recentwork. These diagnostic tools are now
close and could also be used to identify the patterns of genes and immunological components
that are responsible for the control of M. leprae growth in the majority of those exposed to
infection. The leprosy research community should be supported to exploit the huge wealth of
knowledge and expertise in the tuberculosis ﬁeld and apply it to leprosy. Such tools are needed
to effectively interrupt the transmission of leprosy.
36
These studies need to be funded and
carried out now, while there are still experienced leprosy clinicians and ﬁeld staff, as well as
skilled laboratory scientists. The laboratory research community must not give up now, just
when there is a real prospect of imminent breakthroughs and new tools for leprosy, that
are derived from so much underpinning research from not only leprosy but also tuberculosis.
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